Drug Profile


Alternative Names: BIBW 2992 MA2; BIBW-2992; Gilotrif; Giotrif; Tomtovok; Tovok; Xovoltib

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Developer AIO Studien gGmbH; Boehringer Ingelheim; European Organisation for Research and Treatment of Cancer; Merck & Co
  • Class Antineoplastics; Quinazolines; Radiation-sensitising agents; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Squamous cell cancer
  • Phase III Breast cancer; Head and neck cancer
  • Phase II Glioma; Urogenital cancer
  • Phase I Glioblastoma; Rhabdomyosarcoma; Solid tumours
  • No development reported Colorectal cancer; Prostate cancer

Most Recent Events

  • 01 Mar 2017 Registered for Non-small cell lung cancer (First-line therapy, Late-stage disease) in China (PO)
  • 01 Mar 2017 Registered for Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease) in China (PO)
  • 09 Feb 2017 Phase-II clinical trials in Squamous cell cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top